{"id":"W2981921261","doi":"10.1093/ofid/ofz360.2421","title":"2744. A Phase I Randomized, Observer-Blind, Controlled, Dose Escalation Trial of the Safety and Tolerability of a Single Intramuscular Dose of a PAL Adjuvant (Laboratory Code, FB-631) Co-administered with Seasonal TIV (2013–2014) to Healthy Adults ≥18–50 Years of Age","year":2019,"lang":"en","type":"article","venue":"Open Forum Infectious Diseases","topic":"Influenza Virus Research Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"Université de Sherbrooke; NOSM University; Centre Hospitalier de l’Université de Montréal; Université Laval; University of Saskatchewan; Nova Scotia Health Authority; Izaak Walton Killam Health Centre; Dalhousie University","funders":"","keywords":"Medicine; ELISPOT; Adjuvant; Tolerability; Immunogenicity; Reactogenicity; Immunology; Adverse effect; Peripheral blood mononuclear cell; Internal medicine; Virology; Antibody; Antigen; CD8; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001623187,0.002235963,0.001906795,0.0003952203,0.0004358661,0.0006975211,0.0008369464,0.001707567,0.009672116],"category_scores_gemma":[0.00135422,0.0008715878,0.000932369,0.0002672577,0.001440162,0.0008096896,0.0003711379,0.003322106,0.001932625],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005754448,"about_ca_system_score_gemma":0.001543355,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004369404,"about_ca_topic_score_gemma":0.0009928856,"domain_scores_codex":[0.9992781,0.0003013888,0.00003255549,0.000171339,0.00006370378,0.0001528696],"domain_scores_gemma":[0.9990827,0.00020627,0.0001804192,0.00008628084,0.00009976029,0.0003444592],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9401695,0.03301273,0.0003609398,0.0003310491,0.0001760895,0.00004247155,0.00004789849,0.000409488,0.01358617,0.0001528643,0.001344915,0.0103658],"study_design_scores_gemma":[0.7053455,0.2899079,0.001333811,0.00001952245,0.00008727888,0.00002526403,0.00001413438,0.0004190915,0.001792204,0.0001501818,0.0008903812,0.00001466383],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9771742,0.001292897,0.001122314,0.0004327291,0.0007144404,0.01423955,0.001735386,0.0002047129,0.003083798],"genre_scores_gemma":[0.9643735,0.001103542,0.003319131,0.00123332,0.0003852684,0.01844969,0.001506076,0.00005738012,0.009572159],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.009672116,"threshold_uncertainty_score":0.03235644,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03284349924268474,"score_gpt":0.354044225918548,"score_spread":0.3212007266758632,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}